Mabs - Bioprocess Development Forum

Articles Regulatory

August 8, 2024

Since the FDA approved the first monoclonal based therapy in 1985, mAbs have had significant…

Ross Burns

Articles Downstream

May 30, 2024

Significant operational improvements can be achieved by intensified continuous processes compared to standard batch processes.

Ross Burns

Articles

September 21, 2023

The growth in the formulation of drugs suitable for delivery by subcutaneous (Sub-C) injection...

admin-element

Articles Downstream

June 13, 2023

Continued development of new and next-generation antibodies is spurred by the increasing demand for more…

admin-element

Articles

March 30, 2016

The Chinese hamster ovary (CHO) cell lines used for the production of recombinant therapeutic proteins...

admin-element

Articles BioPharma Upstream

February 18, 2016

The biopharmaceutical industry is growing exponentially, driven by an ever-increasing demand for monoclonal antibodies (mAbs)…

admin-element